1 Cheson BD et al. (2007) Revised response criteria for malignant lymphoma. J. Clin Oncol 25:579-586. 2 Kahl, B. et al. (2013) Preliminary Safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ in patients with relapsed/refractory B-cell lymphoma. Presented at the 12 th International Conference on Malignant Lymphoma, Lugano, Switzerland. 3 Flinn, I et al. (2013) Preliminary Safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ in patients with relapsed/refractory CLL/SLL. Presented at the 12 th International Conference on Malignant Lymphoma, Lugano, Switzerland. 4 Horwitz, S et al. (2013) Preliminary Safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ in patients with relapsed/refractory. Presented at the 12 th International Conference on Malignant Lymphoma, Lugano, Switzerland. 5 Hallek M et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 Guidelines. Blood 111: 5446-5456. 6 Weinberg RA (2007) Cytoplasmic signaling circuitry programs many of the traits of cancer. In Jeffcock E, Zayatz E, and Mickey RK (Eds.) The biology of cancer (pp. 179-183). New York, NY: Garland Science, Taylor & Francis Group.

Copyright Business Wire 2010

If you liked this article you might like

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

5 Stocks Insiders Love Right Now

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume